MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.43

-0.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	5/26/2007 3:50:40 PM
	of 2240

Near-term and future value catalysts [for the record - as reported at the recent Citibank conference: slide 21] Ipilimumab - Monotherapy top-line data expected 2H07, followed by BLA - DTIC combination enrollment completion mid-08, followed by BLA - Phase III initiation in melanoma adjuvant and prostate cancer - Phase II initiation in lung Other Phase III programs - Centocor CNTO 1275 BLA in 2007 - Centocor CNTO 148 BLA in early 2008 - Pfizer CP-675,206 - Genmab HuMax-CD20, HuMax-CD4, HuMax-EGFR Clinical Data/Milestones - MDX-066/MDX-1388 (anti-C.difficile) Phase II completion YE07 - MDX-060 (anti-DC30) plus chemotherapy phase II data 2H07/1H08 - MDX-1100 (anti-IP10) Phase II initiation in inflammation 2H07 - MDX-1106 (anti-PD1) Phase II initiation in cancer YE07 - MDX-1106 (anti-PD1) Phase I initiation in infectious disease mid-07 - MEDI-545 (anti-IFNa) Phase I SLE data expected 2007 - MEDI-545 (anti-IFNa) additional Phase II initiations - MEDI-546 (anti-IFNAR) IND YE07 Others - at least 3 IND filings (proprietary and partners) - Corporate partnerships

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next